Sihe Zhang is an expert in Biochemistry at Nankai University (China). Sihe Zhang has authored 67 publications, the most recent in 2026. SLR score: 273 (community average: 125). How the SLR is computed.

LeadR Profile

Sihe Zhang Nankai University China
273 ScienceLeadR Reputation 273
Network Map

Biochemistry

Subspecialties: Pharmacy - Oncology - Dermatology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1998 - 2026

Source: PubMed

Nankai University

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 67

Citations

Citations: 1 162 1st author: 4 Last author: 35 Unique author: 0


Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
CD147-positive migrasome macropinocytosis promotes HCC sorafenib resistance via inducing vasculogenic mimicry triggered by PI3K/AKT/TWIST1 signaling.
PMID 42297770 — sorafenib, hypoxia, cell death
Cell Death Dis20260
HFB301001, an OX40-based immunotherapy, drives Treg clearance and CTL activation through optimized OX40 receptor clustering.
PMID 41912269 — cells, t-lymphocytes, regulatory, safety, antibodies, neoplasms, immunotherapy, bacteriophages, receptors, ox40, cluster analysis
J Immunother Cancer20260
Multiple protease-activated probody-drug conjugates for treating CD147-positive ovarian cancer with limited toxicity.
PMID 41620149 — cells, pharmaceutical preparations, ovary, neoplasms, ovarian neoplasms, pharmacology, peptide hydrolases, urokinase-type plasminogen activator, therapeutics
Pharmacol Res20260
Sulfatase-Responsive Phase-Separating Peptide Coacervates Target Stress Granules to Reverse Sorafenib Resistance in Hepatocellular Carcinoma.
PMID 41616891 — cells, carcinoma, hepatocellular, pharmaceutical preparations, carrier proteins, sulfatases, stress, physiological, neoplasms, sorafenib, biocompatible materials, apoptosis, drug resistance, rna
Acta Biomater20260
Erratum: Hypoxia-activated selectivity-improved anti-PKM2 antibody combined with prodrug TH-302 for potentiated targeting therapy in hepatocellular carcinoma: Erratum.
PMID 41487912 — carcinoma, hepatocellular, hypoxia, therapeutics, prodrugs
Int J Biol Sci20250

LeadR Networks

Main global connection map